Literature DB >> 6147860

Desacetyl-1-nantradol: a selective prostaglandin antagonist.

W C Horne.   

Abstract

Progress in understanding the action of specific prostaglandins will be facilitated by the discovery of specific antagonists to different types of prostaglandin receptors. It has been suggested that nantradol, a cannabinoid-related compound with strong analgetic properties, is an antagonist for prostaglandin receptors. The interaction of nantradol with the receptors for prostaglandin D2 and prostaglandin I2/E1 on human platelets was examined. Desacetyl-1-nantradol, the active form of the drug, blocked the binding of prostaglandin D2 to platelets and the PGD2-induced stimulation of adenylate cyclase activity, but had no effect on the interaction of prostaglandin E1 with platelets. The data support the hypothesis that desacetyl-1-nantradol binds selectively to some classes of prostaglandin receptors and also suggest that it may be useful for distinguishing among different types of prostaglandin receptors.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6147860     DOI: 10.1016/0262-1746(84)90063-5

Source DB:  PubMed          Journal:  Prostaglandins Leukot Med        ISSN: 0262-1746


  4 in total

1.  AH6809, a prostaglandin DP-receptor blocking drug on human platelets.

Authors:  R J Keery; P Lumley
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

Review 2.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

3.  The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist.

Authors:  H Giles; P Leff; M L Bolofo; M G Kelly; A D Robertson
Journal:  Br J Pharmacol       Date:  1989-02       Impact factor: 8.739

4.  Antagonism of PGD2 vasodepressor responses in the rat in vivo by the novel, selective antagonist, BW A868C.

Authors:  S Hamid-Bloomfield; B J Whittle
Journal:  Br J Pharmacol       Date:  1989-02       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.